<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541448</url>
  </required_header>
  <id_info>
    <org_study_id>PRT DD030316</org_study_id>
    <nct_id>NCT02541448</nct_id>
  </id_info>
  <brief_title>Pneumoperitoneum Management With SurgiQuest AirSeal at Low vs. Higher Pressure ( PRESSURE )</brief_title>
  <acronym>PRESSURE</acronym>
  <official_title>A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related to the Use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at Low VS. Higher Pressure for the Management of Pneumoperitoneum.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynthia Harris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SurgiQuest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SurgiQuest, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate physician preference related to the use of the SURGIQUEST&#xD;
      AIRSEAL® INSUFFLATION SYSTEM (AIS) at low verses high pressure for the management of&#xD;
      pneumoperitoneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate physician preferences related to use of the&#xD;
      SurgiQuest AirSeal Insufflation System (AIS) used at low vs. higher pressures for maintaining&#xD;
      pneumoperitoneum during laparoscopic/robotic surgical procedures.&#xD;
&#xD;
      The study is designed and powered to demonstrate superiority of the AIS used at low&#xD;
      insufflation pressure (9±mmHg ±1mmHg) vs higher pressure (15mmHg ±1mmHg) in relation to a&#xD;
      single key effectiveness measure: Incidence of shoulder pain. Patients will be randomized 1:1&#xD;
      to either AIS with an insufflation pressure target of 9±1mmHg) or to AIS with an insufflation&#xD;
      target pressure of 15±1mmHg.&#xD;
&#xD;
      Secondary outcome measures include severity of shoulder pain measured using a VAS scale and&#xD;
      medication use, procedure time, the number of procedure interruptions, length of hospital&#xD;
      stay, aspects of anesthesia management including end tidal CO2 and the frequency of adverse&#xD;
      events. These outcomes will be evaluated in a controlled population undergoing&#xD;
      laparoscopic/robotic surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">May 18, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of shoulder pain</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 24 hours</time_frame>
    <description>Incidence of reported shoulder pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>AIS at 9±1mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIS at 15±1mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SurgiQuest AIRSEAL® Insufflation System (AIS)</intervention_name>
    <description>The SurgiQuest AirSeal Optical Trocar &amp; Cannula System with integrated Insufflator DPIS 2000 (the &quot;DPIS 2000 System&quot;) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization.</description>
    <arm_group_label>AIS at 15±1mmHg</arm_group_label>
    <arm_group_label>AIS at 9±1mmHg</arm_group_label>
    <other_name>AIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 80 years of age;&#xD;
&#xD;
          2. Capable and willing to give informed consent;&#xD;
&#xD;
          3. Acceptable candidate for an elective, non-emergent laparoscopic/robotic surgery;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Advanced refusal of blood transfusion, if necessary;&#xD;
&#xD;
          2. Active systemic or cutaneous infection or inflammation;&#xD;
&#xD;
          3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;&#xD;
&#xD;
          4. Uncontrolled diabetes mellitus&#xD;
&#xD;
          5. Known, significant history of bleeding diathesis, coagulopathy, Von Willebrand's&#xD;
             disease or current platelet count &lt; 100,000 cells/mm3, baseline INR ≥1.8, or&#xD;
             fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24&#xD;
             hours);&#xD;
&#xD;
          6. Severe co-existing morbidities having a life expectancy of less than 30 days;&#xD;
&#xD;
          7. Currently involved in any other investigational clinical Studies;&#xD;
&#xD;
          8. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than&#xD;
             30%;&#xD;
&#xD;
          9. Renal insufficiency (serum creatinine of &gt; 2.5 mg/dl);&#xD;
&#xD;
         10. Females who are pregnant, planning to become pregnant within 3 months of the&#xD;
             procedure, or lactating;&#xD;
&#xD;
         11. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20&#xD;
             kg/m2);&#xD;
&#xD;
         12. Patients presenting with Ascites -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Miami Hospital, Miami Floridaa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>SurgiQuest, Inc.</investigator_affiliation>
    <investigator_full_name>Cynthia Harris</investigator_full_name>
    <investigator_title>Director of Clinical Studies</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
    <mesh_term>Pneumoperitoneum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

